ACADIA Pharmaceuticals Financial Ratios
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.78+0.20 (+1.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ACADIA Pharmaceuticals ratio analysis
ACADIA Pharmaceuticals earned a net margin of 36.5% in FY 2025, up from 23.6% a year earlier. Gross margin was 91.7% compared with a median of 94.5% over the prior 9 years. Return on equity reached 31.9%, meaning ACADIA Pharmaceuticals generated 0.32 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
ACADIA Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 11.43 | 13.54 | — | — | — | — | — | — | — | — |
| Price / sales | 4.13 | 3.19 | 7.06 | 4.98 | 0.01 | 0.02 | 17.52 | 9.94 | 29.56 | 192.80 |
| Price / book | 3.61 | 4.16 | 11.88 | 6.43 | 0.01 | 0.01 | 8.50 | 4.64 | 11.01 | 6.45 |
| Gross margin | 91.7% | 91.5% | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% |
| Operating margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1,574.1% |
| Net margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1,565.9% |
| Free cash flow margin | 9.8% | 16.4% | 2.3% | -22.0% | -26.2% | -32.5% | -44.9% | -75.8% | -175.0% | -1,211.2% |
| Return on equity (ROE) | 31.9% | 30.9% | -14.2% | -53.9% | -31.0% | -44.9% | -33.7% | -51.2% | -86.3% | -52.4% |
| Return on assets (ROA) | 25.0% | 19.1% | -8.2% | -36.7% | -24.0% | -36.0% | -30.0% | -45.4% | -75.3% | -48.4% |
| Current ratio | 3.83 | 2.38 | 2.42 | 4.04 | 6.43 | 6.77 | 10.16 | 8.83 | 7.62 | 12.87 |
| Revenue growth | 11.9% | 31.8% | 40.4% | 6.8% | 9.6% | 30.3% | 51.5% | 79.2% | 620.7% | 28,311.5% |
| EPS growth | 69.1% | — | — | — | — | — | — | — | — | — |